360 related articles for article (PubMed ID: 15864268)
21. Rocks: multifunctional kinases in cell behaviour.
Riento K; Ridley AJ
Nat Rev Mol Cell Biol; 2003 Jun; 4(6):446-56. PubMed ID: 12778124
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.
Itoh Y; Kimoto K; Imaizumi M; Nakatsuka K
Exp Eye Res; 2007 Mar; 84(3):464-72. PubMed ID: 17217948
[TBL] [Abstract][Full Text] [Related]
23. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells.
Lingor P; Tönges L; Pieper N; Bermel C; Barski E; Planchamp V; Bähr M
Brain; 2008 Jan; 131(Pt 1):250-63. PubMed ID: 18063589
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
Leuchtenberger S; Kummer MP; Kukar T; Czirr E; Teusch N; Sagi SA; Berdeaux R; Pietrzik CU; Ladd TB; Golde TE; Koo EH; Weggen S
J Neurochem; 2006 Jan; 96(2):355-65. PubMed ID: 16300630
[TBL] [Abstract][Full Text] [Related]
25. Chronic fluvastatin treatment alters vascular contraction by inhibiting the Rho/Rho-kinase pathway.
Kansui Y; Fujii K; Goto K; Oniki H; Iida M
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):673-8. PubMed ID: 16895538
[TBL] [Abstract][Full Text] [Related]
26. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
Zohrabian VM; Forzani B; Chau Z; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2009 Jan; 29(1):119-23. PubMed ID: 19331140
[TBL] [Abstract][Full Text] [Related]
27. Critical role of the Rho-kinase pathway in TGF-beta2-dependent collagen gel contraction by retinal pigment epithelial cells.
Miura M; Hata Y; Hirayama K; Kita T; Noda Y; Fujisawa K; Shimokawa H; Ishibashi T
Exp Eye Res; 2006 May; 82(5):849-59. PubMed ID: 16310190
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of Rho-associated kinase (Rho-kinase/ROCK/ROK) substrates by protein kinases A and C.
Kang JH; Jiang Y; Toita R; Oishi J; Kawamura K; Han A; Mori T; Niidome T; Ishida M; Tatematsu K; Tanizawa K; Katayama Y
Biochimie; 2007 Jan; 89(1):39-47. PubMed ID: 16996192
[TBL] [Abstract][Full Text] [Related]
29. [Cardiovascular protective action of Rho-kinase inhibitors].
Hirooka Y
Nihon Rinsho; 2004 Jan; 62(1):161-71. PubMed ID: 14737849
[TBL] [Abstract][Full Text] [Related]
30. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma.
Raad M; El Tal T; Gul R; Mondello S; Zhang Z; Boustany RM; Guingab J; Wang KK; Kobeissy F
Electrophoresis; 2012 Dec; 33(24):3659-68. PubMed ID: 23161464
[TBL] [Abstract][Full Text] [Related]
31. Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration.
Kubo T; Hata K; Yamaguchi A; Yamashita T
Curr Pharm Des; 2007; 13(24):2493-9. PubMed ID: 17692017
[TBL] [Abstract][Full Text] [Related]
32. Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome.
Calò LA; Pagnin E; Davis PA; Sartori M; Semplicini A; Pessina AC
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):e34; author reply e34-5. PubMed ID: 15790936
[No Abstract] [Full Text] [Related]
33. Rho-ROCK inhibition in the treatment of spinal cord injury.
Forgione N; Fehlings MG
World Neurosurg; 2014; 82(3-4):e535-9. PubMed ID: 23298675
[TBL] [Abstract][Full Text] [Related]
34. The development of benzimidazoles as selective rho kinase inhibitors.
Sessions EH; Smolinski M; Wang B; Frackowiak B; Chowdhury S; Yin Y; Chen YT; Ruiz C; Lin L; Pocas J; Schröter T; Cameron MD; LoGrasso P; Feng Y; Bannister TD
Bioorg Med Chem Lett; 2010 Mar; 20(6):1939-43. PubMed ID: 20167489
[TBL] [Abstract][Full Text] [Related]
35. ROCKs as therapeutic targets in cardiovascular diseases.
Rikitake Y; Liao JK
Expert Rev Cardiovasc Ther; 2005 May; 3(3):441-51. PubMed ID: 15889972
[TBL] [Abstract][Full Text] [Related]
36. [Rho-kinase inhibitors for ischemic heart disease].
Mohri M; Shimokawa H
Nihon Rinsho; 2003 May; 61 Suppl 5():874-9. PubMed ID: 12809048
[No Abstract] [Full Text] [Related]
37. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.
Kubo T; Yamaguchi A; Iwata N; Yamashita T
Ther Clin Risk Manag; 2008 Jun; 4(3):605-15. PubMed ID: 18827856
[TBL] [Abstract][Full Text] [Related]
38. Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammation associated with various neurological diseases including autism spectrum disorder.
Alokam R; Singhal S; Srivathsav GS; Garigipati S; Puppala S; Sriram D; Perumal Y
Mol Biosyst; 2015 Feb; 11(2):607-17. PubMed ID: 25465055
[TBL] [Abstract][Full Text] [Related]
39. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges.
Hu E; Lee D
Expert Opin Ther Targets; 2005 Aug; 9(4):715-36. PubMed ID: 16083339
[TBL] [Abstract][Full Text] [Related]
40. Physiological role of ROCKs in the cardiovascular system.
Noma K; Oyama N; Liao JK
Am J Physiol Cell Physiol; 2006 Mar; 290(3):C661-8. PubMed ID: 16469861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
